Modulated Mid-frequency Whole-body Electromyostimulation and Nutritional Therapy in Gastrointestinal Cancer Patients
Launched by UNIVERSITY OF COLOGNE · May 10, 2024
Trial Information
Current as of June 26, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at the effects of a special treatment called modulated mid-frequency whole-body electromyostimulation (WB-EMS) combined with nutritional therapy for patients with gastrointestinal cancers like oesophageal, gastric, duodenal, or colorectal cancer. The goal is to see if this combination can help improve health and recovery for patients who have had surgery but are not currently receiving other therapies.
To participate in the trial, you need to be between the ages of 65 and 74 and have had surgery for one of the types of cancer mentioned. You also need to be cleared by a doctor to participate in exercise programs and provide your consent to join the study. However, there are certain conditions that would exclude you from participating, such as having electronic implants (like pacemakers), certain medical issues, or if you are currently pregnant. If eligible, participants can expect to engage in the study's treatments and closely monitor their health under professional supervision. It’s important to know that this trial is currently not recruiting participants, so it’s still in the planning stages.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients with oesophageal, gastric, duodenal, colon or rectal cancer following surgery without further therapy and with neoadjuvant and adjuvant therapy
- • medical clearance for exercise training
- • written declaration of consent from the study participant
- Exclusion Criteria:
- • Participation in another study on the topic of exercise or nutrition
- • Electronic implants such as pacemakers, pumps, and coronary stents
- • Cardiac arrhythmia
- • Implants in the area of application (e.g. breast implants)
- • Pregnancy
- • Epilepsy
- • Wounds and open skin diseases in the area of application of the electrodes
- • Unhealed operations or bone fractures
- • Acute inflammatory diseases (e.g. inflammation of the intervertebral discs, bones, vessels, or soft tissue)
- • Directly after herniated discs or other instabilities such as large abdominal wall hernias
- • Blood clots (thromboses)
- • Bone diseases with high-grade osteoporosis
- • Increased risk of haemorrhage
- • Fever and illnesses that can be aggravated by physical exertion
- • Untreated high blood pressure
- • Blindness
- • Continuous parenteral nutrition
- • Metal and electronic parts in the body (e.g. prostheses, metal vascular clips, hearing aids/inner ear/cochlear implants, magnetic dental prostheses, pacemakers, contraceptives)
About University Of Cologne
The University of Cologne, a prestigious institution located in Germany, is renowned for its commitment to advancing medical research and education. As a clinical trial sponsor, the university leverages its extensive academic resources and expertise to design and conduct innovative studies aimed at improving patient care and health outcomes. With a focus on collaboration across various disciplines, the University of Cologne emphasizes rigorous scientific methodologies and ethical standards in its clinical research initiatives, contributing significantly to the global medical community and fostering the development of new therapeutic strategies.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Cologne, Nrw, Germany
Patients applied
Trial Officials
Freerk T Baumann, Univ.-Prof.
Principal Investigator
Universitätsklinikum Köln
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported